{Reference Type}: Journal Article
{Title}: Management of Neisseria gonorrhoeae infection: from drug resistance to drug repurposing.
{Author}: Pisano L;Giovannuzzi S;Supuran CT;
{Journal}: Expert Opin Ther Pat
{Volume}: 34
{Issue}: 6
{Year}: 2024 Jun 14
{Factor}: 6.714
{DOI}: 10.1080/13543776.2024.2367005
{Abstract}: <B>UNASSIGNED: </B>Neisseria gonorrhoeae is a common sexually transmitted disease connected with extensive drug resistance to many antibiotics. Presently, only expanded spectrum cephalosporins (ceftriaxone and cefixime) and azithromycin remain useful for its management.<BR><B>UNASSIGNED: </B>New chemotypes for the classical antibiotic drug target gyrase/topoisomerase IV afforded inhibitors with potent binding to these enzymes, with an inhibition mechanism distinct from that of fluoroquinolones, and thus less prone to mutations. The α-carbonic anhydrase from the genome of this bacterium (NgCAα) was also validated as an antibacterial target.<BR><B>UNASSIGNED: </B>By exploiting different subunits from the gyrase/topoisomerase IV as well as new chemotypes, two new antibiotics reached Phase II/III clinical trials, zoliflodacin and gepotidacin. They possess a novel inhibition mechanism, binding in distinct parts of the enzyme compared to the fluoroquinolones. Other chemotypes with inhibitory activity in these enzymes were also reported. NgCAα inhibitors belonging to a variety of classes were obtained, with several sulfonamides showing MIC values in the range of 0.25-4 µg/mL and significant activity in animal models of this infection. Acetazolamide and similar CA inhibitors might thus be repurposed as antiinfectives. The scientific/patent literature has been searched for on PubMed, ScienceDirect, Espacenet, and PatentGuru, from 2016 to 2024.